Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

Ridgeback and Merck have partnered to develop molnupiravir and will share profits. In some of the children Denison treats as the director of pediatric infectious diseases at VUMC, remdesivir ...

Twenty-seven drug makers have signed onto a deal to manufacture a generic version of molnupiravir, Merck's oral antiviral for the treatment of COVID-19.The deal will allow affordable access to the ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

Merck & Co and Ridgeback's oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with mild to moderate COVID-19 who are at increased risk of ...

This article was initially published on Wednesday and has been updated on Thursday after the FDA authorized Merck's antiviral pill molnupiravir. Read next ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

The United Kingdom Thursday became the first country in the world to authorize the use of molnupiravir, a pill developed by US laboratories Merck, to treat COVID-19. “Today is a historic day for ...

FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by ...